How good are our guidelines? Four years of experience with the SAMJ’s AGREE II review of submitted clinical practice guidelines by Kredo, T et al.
883       November 2018, Vol. 108, No. 11
GUEST EDITORIAL
The South African Medical Journal (SAMJ) is an established source 
of clinical practice guidelines (CPGs) serving the local healthcare 
community. CPGs link professional societies and clinicians by 
guiding best practice through the collation and interpretation of the 
best available evidence. Not only are CPGs important in standardising 
the quality of patient care, but they also assist with medicine selection 
and resource allocation decisions, adjudicating medicolegal claims, 
and promoting equity by influencing medicine access and health 
system organisation.[1]
In 2014, the SAMJ appointed an editorial subcommittee to review 
CPGs submitted for publication.[2] This was in response to several 
concerns, including the global shift in CPG quality requirements, 
the potential effect of poor-quality CPGs on healthcare quality and 
cost, and the challenges South African (SA) CPG developers face 
in meeting new standards. This editorial reflects on the SAMJ CPG 
review subcommittee’s experience over the past 4 years and describes 
the value of more robust CPG development.
Evolution of CPG development
Early CPGs were essentially narrative reviews linked to 
recommendations of indeterminate validity. Over the past few decades, 
CPG development has become more rigorous by transparently 
considering evidence of efficacy and safety alongside factors such 
as cost, patients’ values and context.[3-5] The Institute of Medicine’s 
concept of a CPG has also evolved since it was first published in 1990 
to the current version: ‘statements that include recommendations 
intended to optimise patient care that are informed by a systematic 
review of evidence and an assessment of the benefits and harms of 
alternative care options’.[3]
The World Health Organization (WHO) is a recognised source of 
CPGs. However, in 2007, an audit of the WHO’s CPG development 
processes uncovered several shortcomings.[6] Methods for development 
were not transparent and guidance was biased towards expert opinion 
rather than reflecting published evidence.[6] This audit led to new CPG 
standards across all WHO programmes, as well as the introduction of 
a guidelines review committee. The committee assesses quality and 
approves CPGs at several stages of development, from planning to 
final dissemination, and requires the use of a systematic approach to 
grade the overall quality of evidence (Grading of Recommendations 
Assessment, Development and Evaluation (GRADE)).[7] As a result, 
a repeat audit in 2010 found improvements in the quality and 
credibility of WHO CPGs.[8] The framework used for the audit was 
the Appraisal of Guidelines for Research and Evaluation (AGREE II) 
tool, a validated, peer-reviewed method for evaluating the quality of 
development and reporting of CPGs[9] and the same tool adopted by 
the SAMJ in its CPG editorial review process.[2]
In SA, interviews with national primary care CPG stakeholders 
indicate that there is a perception that CPG processes are progressing 
and transitioning for the better; however, many challenges 
remain. [10] These include transparent use of evidence, management 
of potential conflicts of interest, stakeholder consultation and 
co-ordination across guideline groups and sectors, and processes 
for adaptation to local context.[11] The underlying reasons include 
financial constraints and limited technical capacity.[10,11] These 
issues highlight potential vulnerabilities in local CPG development, 
recognised by local developers, further substantiating the SAMJ’s 
decision to implement its CPG review process and the adoption of 
the AGREE II tool.
AGREE II as a tool to audit guideline 
quality and vulnerabilities
The AGREE II tool includes six domains of CPG quality:[9]
• Domain 1. Scope and purpose ‘is concerned with the overall aim 
of the CPG, the specific health questions, and the target patient 
population’.
• Domain 2. Stakeholder involvement ‘focuses on the extent to 
which the CPG was developed by the appropriate stakeholders and 
represents the views of its intended users’.
• Domain 3. Rigour of development ‘relates to the process used to 
gather and synthesise the evidence, the methods to formulate the 
recommendations, and to update them’.
• Domain 4. Clarity of presentation ‘deals with the language, 
structure, and format of the CPG’.
• Domain 5. Applicability ‘pertains to the likely barriers and 
facilitators to implementation, strategies to improve uptake, and 
resource implications of applying the CPG’.
• Domain 6. Editorial independence ‘is concerned with the 
formulation of recommendations not being unduly biased by 
competing interests’.
Of these domains, the editorial subcommittee considers two ‘non-
negotiable’ – that is, two domains that, if not addressed, are likely 
to undermine CPG validity by the presentation of potentially 
inaccurate or biased recommendations. These are domain 3 (rigour 
of development) and domain 6 (editorial independence and CPG 
funding).
Several studies systematically evaluating the quality of CPGs from 
SA have consistently found moderate to poor reporting, particularly 
in these domains.[12-14] Given the major concern that poor-quality 
CPGs may result in inefficient use of limited resources or potential 
harm, and the global progress in standards for CPG reporting, these 
issues cannot be overlooked.
Recognising and addressing challenges 
to credible guidelines
A study comparing two iterations of the American College of Chest 
Physicians Antithrombotic Guidelines found that when interests 
are present, recommendations are likely to be swayed in biased 
ways. [15] In CPG development, some CPG panels may aim to avoid 
all conflicts of interest; however, more often steps are taken to ensure 
that the chair of a CPG process has no potential interests in the CPG 
and that the rest of the committee’s interests (be they financial or 
non-financial) are actively managed.[16] This includes recusal from 
decisions involving interventions that they may favour by virtue of 
research done or funding received.
Reviewing the CPG submissions since the editorial subcommittee’s 
inception, the overwhelming observation has been that several of 
the AGREE II domains are poorly reported. Of the seven CPGs 
reviewed, the domains describing the ‘scope and purpose’ and ‘clarity 
and presentation’ attained good average scores of 70%. However, 
domains describing the rigour of the process or methods, or editorial 
independence from funding sources, or suggesting considerations for 
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applicability or implementation, all scored 
below 20% (Fig. 1). Of the CPGs submitted, 
only a minority addressed peer review and 
were subse quently published in the SAMJ, 
with the others opting for alternative 
publication options.
The editorial subcommittee also found 
that many local CPGs are adapted from 
CPGs developed in other countries, or from 
multilateral organisations such as the WHO. 
Adapting CPGs is a well-recognised and 
expedient approach to CPG development, 
and reduces cost and time if new systematic 
reviews are not required. This is an 
appropriate approach for countries such as 
SA with limited CPG resources. However, 
adapting a CPG to a local setting does 
not obviate the need for transparent and 
explicit methods, including the management 
of interests.[17,18] Specifically, rather than 
wholesale and uncritical adoption of a 
CPG, adaptation requires a concerted and 
documented process considering locally 
relevant issues affecting anticipated health 
benefits and risks, as well as costs and 
feasibility. Where possible, SA CPGs should 
also note any major differences between 
their recommendations and those stated in 
already existing standard treatment CPGs 
or policies in the public sector. Convergence 
between private and public sector CPGs is 
an important component of SA’s trajectory 
towards universal health coverage.
Expert opinion and 
guideline development
Expert opinion is at the core of the CPG 
development process. Experts play a key 
role in defining priorities, leading CPG 
development and supporting imple-
mentation. They should also lead the 
consideration of the balance of benefits 
and harms in making recommendations, 
including review of evidence about 
efficacy, harm, costs, stakeholders’ values/
preferences, and context.[19,20] Many tools 
are available to assist in the development of 
rigorous and transparent CPGs, including 
the Guidelines 2.0 checklist, a project that 
systematically compiled all potential steps 
from ‘Guidelines for guidelines’ manuals. [5] 
Given that few groups have the time, 
technical expertise or funds to follow every 
step, there are simpler guides. For example, 
the AGREE II tool can be used as a checklist 
for key quality features.[9] There is also 
an online CPG tool developed with SA 
CPG developers in mind that describes 






The users of CPGs should be mindful of 
the difference between articles that present 
recommendations or reviews of clinical 
practice, which often simply reflect the 
viewpoint of an interested party or group of 
specialists, and a CPG that has undergone 
the rigorous development and evaluation 
process required to meet current standards.
Conclusions
Meeting international standards for local 
CPG development is challenging, but basic 
issues such as evidence scrutiny and under-
standing of potential conflicts of interest are 
important. The CPG editorial subcommittee 
aims to assist the SAMJ in ensuring that 
clinicians and readers receive credible, trust-
worthy CPGs to inform SA clinical care. 
There is a further undertaking to support 
CPG developers by sharing best practice 
and tools needed for the construction and 
publication of sound, locally relevant CPGs. 
The subcommittee looks forward to ongo-
ing collaboration with stakeholders as we 
collectively seek to improve the delivery of 
healthcare in SA.
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Guideline 1          Guideline 2          Guideline 3         Guideline 4         Guideline 5         Guideline 6         Guideline 7Fig. 1. AGREE II percentage scores of seven CPGs submitted to SAMJ. (CPG = clinical practice guideline.)
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